Alkermes
potential clinical utility limited by severe toxicities clinical evaluation limited due to severe toxicities associated with systemic exposure to and its narrow therapeutic index systemic administration associated with the potential for rapid development of lethal inflammatory syndrome ongoing efforts in seeking to develop strategies for tumor localized delivery gene therapy viral delivery primarily based on it administration alkermes design intentions for engineered harness the therapeutic potential of address delivery challenges associated with it approaches avoid toxicity associated with systemic exposure to cancer front cancer res august cancer res index | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
103 of 144
Related slides by other companies
Investor Presentation
May 2023
Investor Presentation
August 2023
Investor Presentation
November 2023
Results
August 2021
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io